MK-0677 Boosts Growth Factor in Hemodialysis Patients
Background
Patients undergoing hemodialysis for chronic kidney disease (CKD) often suffer from growth hormone (GH) and insulin-like growth factor 1 (IGF-1) deficiency, leading to muscle wasting and poor nutritional status. Replenishing IGF-1 could improve these outcomes, but current therapies have limitations. This study aimed to determine whether an oral ghrelin receptor agonist could safely and effectively increase IGF-1 in this vulnerable population.
Results
The study found that MK-0677 significantly increased serum IGF-1 levels compared to placebo. The MK-0677 group experienced a 43% increase in IGF-1 from baseline (p<0.01), whereas the placebo group saw only an 8% increase. Serum GH levels also showed a 1.8-fold increase (p<0.01) in the MK-0677 group. No significant changes were observed in IGFBP-3 levels between the groups, suggesting the increase in IGF-1 was largely unbound and bioavailable. The treatment was well-tolerated, with no significant adverse events reported. The most significant finding was the 43% increase in serum insulin-like growth factor 1 (IGF-1) in patients treated with MK-0677 compared to placebo.
Why It Matters
This study provides compelling evidence that MK-0677, an oral ghrelin receptor agonist, can effectively increase IGF-1 levels in hemodialysis patients. This is a critical step towards addressing the IGF-1 deficiency often seen in this population, which contributes to muscle wasting and poor quality of life. This suggests MK-0677 could be a promising oral therapy to improve nutritional status and muscle mass in hemodialysis patients. Future research should focus on larger, longer-term Phase II and III clinical trials to evaluate the impact of sustained IGF-1 elevation on clinical outcomes such as muscle strength, body composition, and overall patient well-being.